Случай успешного хирургического лечения трофической язвы роговицы

    1. Mastropasqua L, et al. Understanding the Pathogenesis of Neurotrophic Keratitis: The Role of Corneal Nerves. Journal of cellular physiology. 2017;232(4): 717–724.

    2. Pflugfelder SC, et al. Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial. Ophthalmology. 2020;127(1): 14–26.

    3. Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clinical ophthalmology (Auckland, N.Z.). 2014;8: 571–579.

    4. Saad S, et al. Neurotrophic keratitis: Frequency, etiologies, clinical management and outcomes. The ocular surface. 2020;18(2): 231–236.

    5. Bonini S, et al. Phase II Randomized, Double-Masked, VehicleControlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis. Ophthalmology. 2018;125(9): 1332–1343.

    6. Bremond-Gignac D, et al. Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers. Expert opinion on investigational drugs. 2019;28(11): 1013–1020.

    7. Gouvea L, Penatti R, Rocha KM. Neurotrophic keratitis after penetrating keratoplasty for lattice dystrophy. American Journal of Ophthalmology Case Reports. 2021;22: 101058.